RT Journal Article
T1 Hypersensitivity Reactions to Multiple Iodinated Contrast Media.
A1 Doña, Inmaculada
A1 Bogas, Gádor
A1 Salas, María
A1 Testera, Almudena
A1 Moreno, Esther
A1 Laguna, Jose Julio
A1 Torres, María José
K1 anaphylaxis
K1 drug allergy
K1 drug provocation test
K1 exanthema
K1 hypersensitivity
K1 iodinated contrast media
K1 skin test
K1 urticaria
AB The incidence of hypersensitivity reactions (HSRs) to iodinated contrast media (ICM) has risen over last years, representing an important health problem. HSRs to ICMs are classified into immediate reactions (IRs) and non-immediate reactions (NIRs) according to if they occur within 1 h or longer after ICM administration. The diagnosis of HSRs to ICM is complex as skin test (ST) sensitivity ranges widely, and drug provocation test (DPT) protocols are heterogeneous. In this manuscript, we describe the clinical characteristics of a series of patients confirmed as HSR to ICM and the diagnosis procedure carried out, looking into those cases confirmed as HSRs to multiple ICMs. For this purpose, we prospectively evaluated patients suggestive of HSRs to ICMs and classified them as IRs or NIRs. STs were carried out using a wide panel of ICMs, and in those with a negative ST, a single-blind placebo controlled DPT was performed with the culprit. If ST or DPT were positive, then tolerance was assessed with an alternative negative ST ICM. We included 101 cases (12 IRs and 89 NIRs) confirmed as allergic. Among them, 36 (35.64%) cases were allergic to more than one ICM (8 IRs and 28 NIRs). The most common ICM involved were iomeprol and iodixanol. Although not statistically significant, the percentage of patients reporting anaphylaxis was higher in patients allergic to multiple ICMs compared with patients allergic to a single ICM (50 vs. 25%). Likewise, the percentage of positive results in STs was higher in patients allergic to multiple ICMs compared with those allergic to a single ICM (for IR 62.5 vs. 25%, p > 0.05; and for NIR, 85.71 vs. 24.59%, p  0.05; and for NIR, 85.71 vs. 24.59%, p
SN 1663-9812
YR 2020
FD 2020-09-23
LK https://hdl.handle.net/10668/26839
UL https://hdl.handle.net/10668/26839
LA en
DS RISalud
RD Apr 5, 2025